
Is the biotech IPO frenzy in the US headed for a fall?
That is the question posed by the editor of a renowned US biotech news website, John D. Carroll, in a special report following the latest wave of IPOs in the US where several immature companies have entered the market at excessive prices.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app